Austin American-Statesman

US prescripti­on prices generally double those of other countries

- Samantha Putterman PolitiFact.com

It’s well documented that Americans pay high prices for health care. But do they pay double or more for prescripti­ons compared with the rest of the world? That’s what President Joe Biden said.

“If I put you on Air Force One with me, and you have a prescripti­on — no matter what it’s for, minor or major — and I flew you to Toronto or flew to London or flew you to Brazil or flew you anywhere in the world, I can get you that prescripti­on filled for somewhere between 40 to 60 percent less than it costs here,” Biden said Feb. 22 at a campaign reception in California.

He followed up by touting provisions in the 2022 Inflation Reduction Act to lower drug prices, including capping insulin at $35 a month for Medicare enrollees and limiting older Americans’ out-of-pocket prescripti­on spending to $2,000 per year starting in 2025. The law also authorized Medicare to negotiate prices directly with drug companies for 10 prescripti­on drugs, a list that will expand over time.

Research has consistent­ly found that overall, U.S. prescripti­on drug prices are significantly higher, sometimes two to four times, compared with prices in other high-income industrial­ized countries. Unbranded generic drugs are an outlier and are typically cheaper in the U.S. compared with other countries. (Branded generics, a different category, are close to breaking even with other countries).

However, factors including countryspe­cific pricing, confidential rebates and other discounts can obscure actual prices, making comparison­s harder.

“The available evidence suggests that the U.S., on average, has higher prices for prescripti­on drugs, and that’s particular­ly true for brand-name drugs,” said Cynthia Cox, director of the Peterson-KFF Health System Tracker, which tracks trends and issues affecting U.S. health care system performanc­e. “Americans also have relatively high out-of-pocket spending on prescripti­on drugs, compared to people in similarly large and wealthy nations.” Andrew Mulcahy, a senior health economist at Rand Corp., a nonpartisa­n research organizati­on, agreed that Biden’s overall sentiment is on target but ignores some complexiti­es.

He said price comparison­s his team has conducted reflect the amounts wholesaler­s pay manufactur­ers for their drugs, which can differ sharply from prices consumers and their drug plans pay.

“In many of those other countries (patients) pay nothing,” Mulcahy said, “so I think that’s part of the complicati­on here when we talk about prices; there are so many different drugs, prices and systems at work.”

What internatio­nal drug pricing comparison­s show

A 2024 Rand study that Mulcahy led found that across all drugs, U.S. prices were 2.78 times higher than prices in 33 other countries, based on 2022 data. The report evaluated most countries in the Organizati­on for Economic Cooperatio­n and Developmen­t, a group of 38 advanced, industrial­ized nations.

The gap was largest for brand-name drugs, the study found, with U.S. prices averaging 4.22 times higher than those in the studied nations. After adjusting for manufactur­er-funded rebates, U.S. prices for brand-name drugs remained more than three times higher than prices in other countries. on the different price adjustment­s.

The U.S. pays less for one prescripti­on category: unbranded, generic drugs, which are about 33% less than in other studied countries. These types of drugs account for about 90% of filled prescripti­ons in the U.S., yet make up only one-fifth of overall prescripti­on spending.

“The analysis used manufactur­er gross prices for drugs because net prices — the amounts ultimately retained by manufactur­ers after negotiated rebates and other discounts are applied — are not systematic­ally available,” a news release about the report said.

People with health insurance pay prices that include both markups and discounts negotiated with insurers. Uninsured people may pay a pharmacy’s “usual and customary” price — which tends to be higher than net prices paid by others— or a lower amount using a manufactur­er discount program. But many of these adjustment­s are confidential, making it hard to quantify how they affect net prices.

In 2021, the Government Accountabi­lity Office released an analysis of prices of 20 brand-name drugs in the U.S., Canada, Australia and France. The study found that retail prices were more than two to four times higher in the U.S.

Like Rand, the agency adjusted for rebates and other price concession­s for its U.S. estimate, but the other countries’ estimates reflected gross prices without potential discounts.

“As a result, the actual differences between U.S. prices and those of the other countries were likely larger than GAO estimates,” the report said.

Another analysis by the PetersonKF­F Health System Tracker that Cox coauthored compared the prices of seven brand-name drugs in the U.S., Germany, the Netherland­s and the United Kingdom, and found that some U.S. prices were two to four times higher. For unbranded, generic drugs, the price gaps were smaller.

“Despite the fact that the U.S. pays less for generic drugs and Americans appear to use more generic drugs than people in other countries, this did not offset the higher prices paid for brandname drugs,” Cox said.

The Peterson-KFF report, using 2019 OECD data, found that the U.S. spent about $1,126 per person on prescripti­on medicines, higher than any peer nation, with comparable countries spending $552. This includes spending by insurers and out-of-pocket consumer costs.

“Private and public insurance programs cover a similar share of prescripti­on medicine spending in the U.S. compared to peer nations,” the report noted. “However, the steep costs in the U.S. still contribute to high U.S. healthcare spending and are passed onto Americans in the form of higher premiums and taxpayer-funded public programs.”

PolitiFact’s ruling

Biden said, if you went “anywhere in the world,” you could get a prescripti­on filled for 40% to 60% less than it costs in the U.S.

He exaggerate­d by saying “anywhere in the world,” but for comparable highincome, industrial­ized countries, he’s mostly on target.

Research has consistent­ly shown that Americans pay significantly higher prices overall for prescripti­on medication, averaging two times to four times more, depending on the study. The U.S. pays less for unbranded, generic drugs, but those lower prices don’t offset the higher prices paid for brand-name drugs, researcher­s said.

Factors including country-specific pricing, confidential rebates and other discounts also obscure true consumer prices, making comparison­s difficult.

Biden’s statement is accurate but needs clarification and additional informatio­n. We rate it Mostly True.

PolitiFact copy chief Matthew Crowley contribute­d to this report.

 ?? ?? Biden
Biden

Newspapers in English

Newspapers from United States